-
Alipogene tiparvovec, sold
under the
brand name Glybera, is a gene
therapy treatment designed to
reverse lipoprotein lipase deficiency (LPLD), a rare...
-
researchers to make much more
precise genome changes at
exact locations. Cost –
Alipogene tiparvovec or Glybera, for example, at a cost of $1.6
million per patient...
-
radiopharmaceuticals (e.g. iobenguane) -vec for gene
therapy vectors (e.g.
alipogene tiparvovec) -meran for
messenger RNA
products (e.g. tozinameran) The term...
-
blocking agents.[citation needed] In 2012, the
European Commission approved alipogene tiparvovec (Glybera), a gene
therapy for
adults diagnosed with familial...
-
Peptides and
glycopeptides nesiritide,
octreotide -vec Gene
therapy vectors Alipogene tiparvovec -ast Anti-asthmatic zafirlukast,
seratrodast -caine
local anesthetic...
- used in
basic neuroscience research.
Following the
approval of the AAV
Alipogene tiparvovec in
Europe in 2012, in 2017, the FDA
approved the
first AAV-based...
-
chronic lymphocytic leukemia (CLL), and Parkinson's disease. In 2012,
Alipogene tiparvovec became the
first gene
therapy treatment to be
approved for...
-
alinastine (INN)
Alinia (Romark Laboratories)
alinidine (INN)
alipamide (INN)
alipogene tiparvovec (INN)
alisertib (INN, USAN)
aliskiren (USAN)
alisporivir INN...
- C,
Tremblay G, et al. (April 2013). "Efficacy and long-term
safety of
alipogene tiparvovec (AAV1-LPLS447X) gene
therapy for
lipoprotein lipase deficiency:...
-
pyridoxal 5-phosphate
glutamate C10AX08
Policosanol C10AX09
Ezetimibe C10AX10
Alipogene tiparvovec C10AX11
Mipomersen C10AX12
Lomitapide C10AX13 Evolo****ab C10AX14...
